Skip to main content

Advertisement

Table 1 Summary of major clinical trials on aerosol measles vaccines presented to the expert group for stage II of the CHNRI process

From: An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children

Reference MV Strain Age group Seroconversion as defined by authors
A.Dilraj et al [46] MV-Schwarz ( s/c, aerosol), MV- Edmonston-Zagreb ( s/c, aerosol) 992 participants 5-14 years Seroconversion rates (defined as four fold increase in antibody level): EZ Aerosol – 84.7% EZ sc – 78.8% SW Aerosol – 22.7% SW sc – 62.6%
A.Dilraj et al [47] MV-Schwarz ( s/c), MV- Edmonston-Zagreb ( s/c, aerosol) 337 participants 5-14 years Seroconversion (defined as four fold increase in antibody level) at 6 years after revaccination: EZ Aerosol – 86% EZ sc – 73% SW sc – 58%
J.A.Bellanti et al [48] MV- Edmonston-Zagreb ( s/c, aerosol) 49 participants 6-7 years The mean Specific anti-measles IgG antibody: EZ sc - 22.9 ± 4.6 EZ aerosol - 53.4 ± 9.4 Results are reported as mean _ µg/ml ± standard error of the mean
J.V.Bennett et al [49] MV-Schwarz ( s/c), MV- Edmonston-Zagreb ( s/c, aerosol) 1624 participants 6-8 years Change from seronegative to seropositive, >= 120 mIU/ml EZ aerosol – 65% EZ sc – 4% SW sc – 23%
R.M.Wong-Chew et al [50] MV- Edmonston-Zagreb ( s/c, aerosol) 114 participants 11-13 months Seroresponse rates as defined by four fold increase in antibody level: EZ aerosol – 89.8% EZ sc – 100%
R.M.Wong-Chew et al [51] MV- Edmonston-Zagreb ( s/c, aerosol) 129 participants 8-10 months Seroresponse rates as defined by four fold increase in antibody level: EZ Aerosol – 42% EZ sc – 67%